MAP2K mutants constitutively phosphorylate MAPKs

Stable Identifier
R-HSA-9652165
Type
Reaction [transition]
Species
Homo sapiens
Compartment
cytosol
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
MAP2K mutants constitutively phosphorylate MAPKs
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Although they occur at much lower frequently than mutations in upstream components of the RAS signaling pathway, activating mutations in MAP2K proteins, encoding MEK1 and MEK2, have been identified in a number of cancers and germline disorders (Marks et al, 2008; Murugan et al, 2009). These mutations cluster in the N-terminal autoinhibitory domain or in the catalytic domain and lead to constitutively active forms of the proteins that phosphorylate MAPK1 and MAPK2 (ERK2 and ERK1) independent of upstream signaling (Nikolaev et al, 2011; Rodriguez-Viciana and Rauen, 2008; Borttoff et al, 1995; Marks et al, 2008; Estep et al, 2007; Van Allen et al, 2014; Chen et al, 2014; Wagle et al, 2011; Waterfall et al, 2014; Rauen et al, 2010; reviewed in Samatar and Poulikakos, 2014; Rauen, 2013; Bezniakow et al, 2014).
Literature References
PubMed ID Title Journal Year
20358587 Molecular and functional analysis of a novel MEK2 mutation in cardio-facio-cutaneous syndrome: transmission through four generations

Sampath, S, Lacassie, Y, Tidyman, WE, Bale, SJ, Peltier, HM, Estep, AL, Rauen, KA

Am. J. Med. Genet. A 2010
7651428 RAS signalling is abnormal in a c-raf1 MEK1 double mutant

Stone, JC, Agellon, S, Bottorff, D, Stang, S

Mol. Cell. Biol. 1995
24241536 High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias

Waterfall, JJ, Pineda, M, Roth, L, Davis, SR, Kreitman, RJ, Killian, JK, Meltzer, PS, Arons, E, Abaan, OD, Walker, RL

Nat. Genet. 2014
18632602 Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma

Ladanyi, M, Gong, Y, Mardis, ER, Rusch, VW, Ding, L, Levine, R, McLellan, MD, Chitale, D, Marks, JL, Michel, K, Golas, B, Thomas, RK, Solit, D, Kasai, Y, Wilson, RK, Pao, W

Cancer Res. 2008
24265153 The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

Taylor-Weiner, A, Gutzmer, R, Rosenberg, M, Treacy, DJ, Goldinger, SM, Gogas, HJ, Dermatologic Cooperative Oncology Group of Germany (DeCOG), -, Van Allen, EM, Garraway, LA, Farlow, D, Trefzer, U, Egberts, F, Place, CS, McKenna, A, Gabriel, SB, Schadendorf, D, Hodis, E, Carter, SL, Kryukov, GV, Wagle, N, Whittaker, S, Johannessen, CM, Hassel, JC, Weide, B, Berking, C, Loquai, C, Zimmer, L, Getz, G, Hillen, U, Ugurel, S, Goetz, EM, Cibulskis, K, Sucker, A

Cancer Discov 2014
25435214 Targeting RAS-ERK signalling in cancer: promises and challenges

Poulikakos, PI, Samatar, AA

Nat Rev Drug Discov 2014
22197931 Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma

Xenarios, I, Antonarakis, SE, Guipponi, M, Jongeneel, CV, Rimoldi, D, Speiser, D, Muehlethaler, K, Michielin, O, Zoete, V, Bukach, O, Harshman, K, Halazonetis, TD, Nikolaev, SI, Gehrig, C, Stevenson, BJ, Robyr, D, Beckmann, JS, Iseli, C, Valsesia, A

Nat. Genet. 2011
23875798 The RASopathies

Rauen, KA

Annu Rev Genomics Hum Genet 2013
25182392 The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes

Obersztyn, E, Bezniakow, N, Gos, M

Dev Period Med 2014
25049390 Next-generation sequencing identifies rare variants associated with Noonan syndrome

Reid, JG, Fernandez, M, Neel, BG, Muzny, DM, Yung, CK, Kucherlapati, R, Yu, HW, Chen, PC, Peltekova, VD, Gibbs, RA, Tworog-Dube, E, Roberts, AE, Yin, J, McPherson, JD, Stein, L, Yuan, T, Trinh, QM, Morgan, MB

Proc. Natl. Acad. Sci. U.S.A. 2014
18413255 Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome

Rodriguez-Viciana, P, Rauen, KA

Meth. Enzymol. 2008
21383288 Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

Pochanard, P, Hahn, WC, Emery, C, Kehoe, SM, Davis, MJ, Meyerson, M, Sawyer, A, Berger, MF, Macconaill, LE, Wagle, N, Garraway, LA, Johannessen, CM

J. Clin. Oncol. 2011
18060073 Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy

McCormick, F, Palmer, C, Estep, AL, Rauen, KA

PLoS ONE 2007
Participants
Input
Output
Participates
as an event of
Catalyst Activity

protein serine/threonine kinase activity of MAP2K1 and MAP2K2 mutants [cytosol]

Physical Entity
MAP2K1 and MAP2K2 mutants [cytosol] (Homo sapiens)
Activity
protein serine/threonine kinase activity (GO:0004674)
Functional status

Gain of function of MAP2K1 and MAP2K2 mutants [cytosol]

Disease Entity
Status
Disease
Name Identifier Synonyms
cardiofaciocutaneous syndrome DOID:0060233 CFC syndrome, cardio-facial-cutaneous syndrome
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2019-10-25)
Reviewed
Gavathiotis, E  (2020-05-04)
Created
Rothfels, K  (2019-06-27)
Cite Us!